← Back to headlines
EU Approves First Drug to Slow Multiple Sclerosis Disability Progression
The European Commission has approved Sanofi's Cenrifki (tolebrutinib), marking the first drug in the European Union specifically approved to slow the progression of secondary progressive multiple sclerosis (SPMS) without relapses.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
